<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092531</url>
  </required_header>
  <id_info>
    <org_study_id>1 R01 MH111632-01</org_study_id>
    <nct_id>NCT03092531</nct_id>
  </id_info>
  <brief_title>Positive Steps to Enhance Problem Solving Skills</brief_title>
  <acronym>STEPS</acronym>
  <official_title>Adaptive Intervention Strategies Trial for Strengthening Adherence to Antiretroviral HIV Treatment Among Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized control trial is to test the efficacy of a stepped-care &quot;adaptive&quot;&#xD;
      Antiretroviral Therapy (ART) adherence intervention (&quot;Positive STEPS&quot;) for HIV infected&#xD;
      adolescents and young adults, ages 16 to 29. Stepped care is a healthcare delivery model in&#xD;
      which the least resource intensive part of an intervention is delivered first, and only those&#xD;
      who do not improve then receive the high intensity, more resource intensive part of an&#xD;
      intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected adolescents and young adults will be recruited from Providence, Rhode Island,&#xD;
      Boston, Massachusetts and Chicago, Illinois. Participants will be equally randomized to:&#xD;
&#xD;
        1. &quot;Positive STEPS&quot; - a stepped care, adherence intervention with integrated technology&#xD;
           (2-way daily text messaging aimed at improving ART adherence). If text messaging is not&#xD;
           sufficient to overcome the barriers to ART adherence;these individuals will then also&#xD;
           receive the more intensive component based on general principles of cognitive-behavioral&#xD;
           therapy.&#xD;
&#xD;
        2. Standard of Care comparison group including a brief adherence educational session. This&#xD;
           will consist of a review of medications and recommended dosing (i.e., to understand&#xD;
           regimen), adherence expectations, toxicity expectations and medication&#xD;
           misperceptions.The participant will then view a 20-minute animated tutorial which&#xD;
           explains the importance of adherence to antiretroviral medication effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Block randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced HIV Viral Load</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Blood specimen collection tested for HIV Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ART Medication Level in Hair Sample</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Collection of hair sample to measure level of ART</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily ART adherence</measure>
    <time_frame>4 month, 8 month, 12 month</time_frame>
    <description>Monitoring of Wisepill device for electronic adherence data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily ART Adherence</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Self report via research assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced HIV Symptoms</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Medical record review for increase or decrease in symptoms associated with HIV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement in HIV Care</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Number of kept versus number of scheduled visits verified by medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication changes to ART</measure>
    <time_frame>Baseline, 4 month, 8 month, 12 month</time_frame>
    <description>Verified by medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Adherence</condition>
  <arm_group>
    <arm_group_label>Positive STEPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (&quot;social-cognitive cues&quot;). If a participants demonstrates &gt;90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Positive STEPS</intervention_name>
    <description>Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.</description>
    <arm_group_label>Positive STEPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 16 and 29 years of age&#xD;
&#xD;
          -  HIV-infected (perinatally, transfusion, or behaviorally-acquired)&#xD;
&#xD;
          -  Currently taking or prescribed antiretroviral therapy and: 1) Began taking ART &lt; 3&#xD;
             months ago, OR 2) Has been taking ART for &gt;3 AND has missed one or more doses in the&#xD;
             past week or more than 3 doses in the past month.&#xD;
&#xD;
          -  Daily access to a cell phone&#xD;
&#xD;
          -  Has lived in the greater Providence, Boston, or Chicago area greater than three months&#xD;
&#xD;
          -  Self-reports &lt; 90% ART medication adherence in the past month (i.e., missed one or&#xD;
             more doses in the past week or more than 3 doses in the past month) at screening&#xD;
&#xD;
          -  Able to speak and understand English&#xD;
&#xD;
          -  Not currently enrolled in another ART-adherence intervention study&#xD;
&#xD;
          -  Willing and able to complete all study visits in person or remotely via video&#xD;
             conferencing platform&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent due to severe mental or physical illness, cognitive&#xD;
             limitation, or substance intoxication at baseline visit&#xD;
&#xD;
          -  HIV-uninfected&#xD;
&#xD;
          -  Not currently on antiretroviral therapy&#xD;
&#xD;
          -  Does not own a cell phone&#xD;
&#xD;
          -  Has lived in the greater Providence, Boston, or Chicago area for less than three&#xD;
             months or is planning to move outside the area within the next year&#xD;
&#xD;
          -  Self-reports &gt; 90% ART medication adherence in the past month AND has been taking ART&#xD;
             for more than 3 months&#xD;
&#xD;
          -  Unable to speak and understand English&#xD;
&#xD;
          -  Currently enrolled in another ART-adherence intervention study&#xD;
&#xD;
          -  Not willing to and able to complete all study visits in person or remotely via video&#xD;
             conferencing platform&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Mimiaga, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA, School of Public Health, Department of Epidemiology, Fielding School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Garofalo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lurie Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew J Mimiaga, ScD, MPH</last_name>
    <phone>617-901-9276</phone>
    <email>mmimiaga@ph.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Garofalo, MD</last_name>
    <phone>800-543-7362</phone>
    <email>rgarofalo@Luriechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lurie Childrens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Garofalo, MD</last_name>
      <phone>800-543-7362</phone>
      <email>rgarofalo@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fenway Health Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Mayer, MD</last_name>
      <phone>617-927-6087</phone>
      <email>kmayer@fenwayhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Olson</last_name>
      <phone>(401) 863 -3292</phone>
      <email>jennifer_olson1@brown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ken Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University School of Public Health</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew J Mimiaga, ScD, MPH</last_name>
      <phone>617-901-9276</phone>
      <email>mmimiaga@ph.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Matthew Mimiaga, ScD, MPH, MA</investigator_full_name>
    <investigator_title>Professor of Epidemiology, UCLA Fielding School of Public Health, and Psychiatry &amp; Biobehavioral Sciences, UCLA David Geffen School of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>ART Adherence</keyword>
  <keyword>Adolescents</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Present at least annually on data collected after the second year when sufficient baseline data is collected. Randomized controlled efficacy trial, we anticipate that most of the papers and data-based projects and presentations will happen in year 5, once baseline data and follow-up assessments have occurred. Sharing findings will involve several papers, including a baseline paper, intervention-specific paper, primary paper describing the study outcomes, secondary outcomes papers and potentially a book that describes the intervention, submitting to lead workshops on the intervention approach at relevant national and international meetings and conferences. Raw data for additional analysis will be available by contacting the Principal Investigators.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03092531/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

